Catalog Number: 4LSC2622
CAS #: N/A
Related CAS #: 38739-13-8 (unlabeled)
Name: [13C6]-3-Bromotyrosine, (S)-2-amino-3-(3-bromo-4-hydroxyphenyl-1,2,3,4,5,6-13C6)propanoic acid
3-Bromotyrosine (BY) is generated from the halogenation of tyrosine residues in plasma proteins via the enzyme Eosinophil peroxidase. The presence of free bromotyrosine in blood or urine is the result of enzymatic degradation of these brominated proteins. A significantly higher concentration of BY was observed in the urine from asthmatic patients than in that from healthy control subjects. Bromotyrosine may be useful for monitoring the activation of eosinophils in asthmatic patients.
Stable isotope labeled 3-Bromotyrosine is intended for use as an internal standard for the quantification of 3-Bromotyrosine by LC or GC-mass spectrometry.
If the number, nature and/or location of stable isotope label atoms (D, 15N, 13C) in this molecule don’t fit with your application, don’t hesitate to contact us to discuss your specific needs.
Stable isotope labeled active pharmaceutical ingredient (API), stable isotope dilution analysis, internal standard, stable isotope labeled standard (SIL), therapeutic drug monitoring (TDM), quantitative bioanalytical method validation, clinical diagnosis, LC/MS method validation, diagnostic breath test, clinical chemistry, diagnostic tools & biomarkers.
- Molecular Formula: C313C6H10BrNO3
- Molecular Weight: 266.04 g/mol
Minimum chemical purity: 95.0 %
Minimum Isotopic Enrichment: 13C ≥99 %
- Solubility: Methanol (MeOH), Dimethylsulfoxide (DMSO),
- HS Code: 284590
3-Bromotyrosine and 3,5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Wu et al Biochemistry, 1999, 38 (12), 3538–354. doi: 10.1021/bi982401l
Enquiry about 4LSC2622 [13C6]-3-Bromotyrosine
We're ready to solve any rare chemicals sourcing or molecular design problem... Give us a shout ! Please fill out this form completely (incomplete form will not be considered).